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Edited by Gunnar von Heijne and Anders LiljasAbstract Ribosomes are ribozymes exerting substrate position-
ing and promoting substrate-mediated catalysis. Peptide-bonds
are formed within a symmetrical region, thus suggesting that
ribosomes evolved by gene-fusion. Remote interactions dominate
substrate positioning at stereochemistry suitable for peptide-
bond formation and elaborate architectural-design guides the
processivity of the reaction by rotatory motion. Nascent proteins
are directed into the exit tunnel at extended conformation, com-
plying with the tunnels narrow entrance. Tunnel dynamics facil-
itate its interactive participation in elongation, discrimination,
cellular signaling and nascent-protein traﬃcking into the chap-
eron-aided folding site. Conformational alterations, induced by
ribosomal-recycling factor, facilitate subunit dissociation.
Remarkably, although antibiotics discrimination is determined
by the identity of a single nucleotide, involved also in resistance,
additional nucleotides dictate antibiotics eﬀectiveness.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights resevered.
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factor1. Symmetry within the asymmetric ribosome
The ribosome, a 2.5 MDa riboprotein assembly is a ribo-
zyme composed of two unequal subunits that associate upon
the initiation of the biosynthetic cycle. m-RNA is being de-
coded at the small subunit, and the peptide bond is being
formed by the large one, in the lower end of a cavity built
mainly of ribosomal RNA. A single protein, L16 (Escherichia
coli nomenclature is used throughout), placed at its upper rim
(Fig. 1a). Despite the ribosome asymmetric nature, a sizable
symmetry-related region relating RNA backbone fold and
nucleotides orientations, rather than nucleotides identities,
was revealed around the peptidyl transferase catalytic site
(PTC) in all known structures (Fig. 1b) [1]. The symmetry-
related region contains 180 nucleotides and extends far beyond
the PTC. It connects all functional centers involved in amino-
acid polymerization, including peptide-bond formation and
decoding sites, as well as the RNA entry and leaving regions*Corresponding author. Fax: +972 8 9343028.
E-mail address: ada.yonath@weizmann.ac.il (A. Yonath).
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doi:10.1016/j.febslet.2004.11.063(Fig. 1b). Ribosomal proteins contacting its exterior [2] include
protein L2, residues 228, 229. These contacts are likely to sta-
bilize the regions conﬁrmation, consistent with the essentiality
of histidine sidechain at L2-229 for nascent-chain elongation
[4], although single peptide bonds can form by protein-free
23S RNA. Similarly, a Zn containing protein (L36) that exists
in several species including Deinococcus radiodurans binds to
the regions non-symmetrical extensions that interact with
the elongation factors [2], seems to contribute to the regions
stability.
The bond connecting the universally conserved single-strand
tRNA-CCA-end with the tRNA-acceptor-stem almost coin-
cides with the symmetry-axis [1,6], indicating that transloca-
tion involves two synchronized motions: a rotation of the
tRNA 3 0 end and an overall mRNA/tRNA sideways shift.
Guided by PTC components, which create its template (Fig.
1c), the rotatory motion results in stereochemistry suitable
for peptide-bond formation and for nascent-chain elongation
[1,5–7]. Furthermore, it places the A-site nucleophilic amine
and the P-site carbonyl-carbon at a distance reachable by the
P-site tRNA A76 O2 0, consistent with its participation in the
peptide-bond formation catalysis [8,9] as well as with recent
biochemical and kinetic ﬁndings [10–12]. Hence, the ribosomal
architecture provides all of the positional elements required for
aminoacid polymerization.
The PTC symmetrical properties suggest that the ribosomal
active site evolved by gene fusion of two separate domains of
similar structures, each hosting part of the catalytic activity.
The preservation of three-dimensional structure of the sym-
metrical region despite the lack of sequence identity demon-
strates the superiority of the architectural RNA elements
that determine the functional eﬃciency. Protein L16, the only
ribosomal protein contributing to tRNA positioning [1,2]
shares similar properties, namely its three-dimensional struc-
ture is conserved in eubacteria and archaea (Fig. 1a) [3],
regardless of the signiﬁcant variability in the aminoacid se-
quences. Thus, verifying the dominance of the rigorous
requirements for accurate substrate positioning throughout
evolution.2. Positioning hierarchy
The geometrical requirements for a successful rotatory mo-
tion are proper A-site binding and initial P-site-tRNA at the
rotated conformation. For this aim the PTC oﬀers twoblished by Elsevier B.V. All rights reserved.
Fig. 1. (a) The PTC cavity in D50S complexed with ASM [1]. The nucleotides forming basepairs with A- and P-site tRNAs are numbered. Inset:
Superposition of D50S protein L16, the only protein residing in the PTC cavity (a), and its mate in H50S, called L10e. (b) Bottom: A superposition of
the RNA backbone of the symmetry-related region in all known structures [3,27,30]. The sub-region containing the A-loop is shown in blue and that
containing the P-loop in green. The symmetry axis is red. The view shows also the ASM 3 0 end at the A-site (blue) and the derived [1] P-site tRNA 3 0
end (green), as atoms. The red ring designates the approximate PTC limits. Top: The symmetry-related region within D50S (ﬁlled by blue and green).
Its extensions are colored cyan. Bring b2a (also called H69 tip); the bridge connecting the large subunit with the decoding region in the small subunit
is yellow. Note that this bridge is also part of the PTC cavity upper rims (a). (c) Various presentations of the region encircle in red (b, bottom). In all,
the A- and P-site components are shown in blue and green, respectively. A2602 and U2585 are marked whenever not covered by other features. The
rotatory motion is illustrated by snapshots obtained by successive rotations of the aminoacylated-tRNA3 0 end from A- (blue) to P-site (green) by 15
each, around the bond connecting the 3 0 end with the rest of the tRNA molecule. The blue-green arrows indicate the direction of the rotatory motion.
(c1) The PTC boundaries scaﬀolding the path of the rotatory motion are colored according to the symmetry sub-regions, as in (b). In (c2–4) ribosomal
features are shown in gray. The rotatory motion anchors, A2602 and U2585, are highlighted in pink and magenta. Four diﬀerent conformation of
A2602 are shown in (c1), with their PDB accession codes. In (c1) the A- to P-site pass is represented by the gradual transfer from blue to green,
whereas in (c3) the volume taken by the rotatory motion is depicted in cyan. (c2) The central part of (c1), viewed from bottom, focusing on the
geometry of the peptide-bond formation site. (c3) Two orthogonal views illustrating the support and guidance given by the ribosome to the rotatory
motion, highlighting the space allocated to this motion within the very crowded neighborhood (left), and the architectural design of the tRNA
backbone, on the right. The rotatory motion is represented by the snapshots shown in (c2), space ﬁlled in cyan.
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pairing with the ﬂipped CCA-end (Fig. 1a), instead of the sin-
gle basepair donor (G2553) at the A-site [13]. Indeed, C75 of
the derived P-site tRNA 3 0 end [1] can readily basepair with
G2251, and the base of C74 is facing that of G2252, so thatonly a minor rearrangement is required for the creation of a
basepair between them.
A-site-tRNA C75 basepairing was observed in all complexes
studied so far [1,14], manifesting its crucial role in substrate
positioning. Nevertheless, this basepairing may not be suﬃ-
Fig. 2. (a) Left: superposition of a long (ASM) and a short tRNA mimics in D50S-PTC [1], together with the rRNA features in their proximity,
including the universal basepair donor. Note that although both compounds are involved in this basepair, their orientations display considerable
diﬀerences. Right: same as in the left, but including substrate analogs bound to H50S [14]. Note the similarity in their overall locations and the
diﬀerences in their orientations in the region of peptide bond formation (encircled). (b) Superposition of the PTC nucleotides in H50S [14] and D50S
[3]. Inset: the overall view. (c) A view perpendicular to of the PTC wall. (d) Sparsomycin binding sites in D50S (Spar-D) and H50S (Spar-H),
illuminating the connection between the binding modes and the ribosome functional states. The ribosomal components are shown in gray. (e) Two
orthogonal views of D50S PTC, together with the rotating moiety, as shown in Fig. 1c, focusing on the conformational alteration of U2585 (from
U2585n to U2585f) induced by streptograminA component of the synergetic antibiotic Synercid. StreptograminB is shown on the right, indicating the
mode of synergism enhancing the antibiotic action. The dotted line designates the approximate location of the new peptide bond and T represents the
upper side of the tunnel. (f) Clindamycin-binding site on the superposition of H50S and D50S PTC.
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be created by tRNA 3 0 end analogs, such as the fragment reac-
tion reactants while placed at diverse orientations (Fig. 2a),
most of which requiring conformational rearrangements [14].
In contrast, productive substrate orientation has been
observed for a substrate analog mimicking the tRNA accep-
tor-stem, such as ASM, a 35 nucleotides substrate analog mim-
icking the A-site tRNA acceptor stem and its aminoacylated 3 0
end (Fig. 1a). The detection of approximate symmetry in com-
plexes with partially disordered or inaccurate intermediates
[14] or with tRNA analogs too short to reach the PTC upper
side demonstrates the relative ease of accommodating com-
pounds resembling tRNA-3 0 end in the PTC [15,16], and ratio-
nalizes the need for exploring ﬁve diﬀerent H50S–puromycin
complexes for discovering the need for additional rearrange-
ments of such analogs.
We conclude, therefore, that global tRNA placement is dic-
tated by its size and shape and the tRNA-CCA-end basepair-ing determines its approximate location within the symmetrical
ribosomal frame. The ﬁne-tuning of the correct aminoacy-
lated-3 0 end positioning, mandatory for eﬃcient peptide-bond
formation, is governed by remote interactions of the tRNA
acceptor-stem with the PTC upper rim [15,16]. Consistent with
recent ﬁndings that mutations in PTC nucleotides proximal to
the catalytic site do not inﬂuence the rate of peptide-bond for-
mation by tRNA molecules, but cause substantial increase in
reaction rate when short tRNA analogs serve as substrates
[11]. This hierarchy suggests that controlling accurate substrate
positioning by remote interactions is designed for allowing
PTC ﬂexibility required for its various functions.3. PTC ﬂexibility, conformation rearrangements and chirality
The placement hierarchy hints that the PTC may be involved
in substrate reorganizations when the initial orientation cannot
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to consume time, causing low rate of peptide-bond formation
by short puromycin derivatives [11,14]. PTC involvement in
substrate rearrangement requires considerable ﬂexibility, con-
sistent with PTC conformational variability observed in the
diﬀerent crystal structures (Fig. 2b) [3,17], which could be con-
nected to active–inactive transitions revealed three decades ago
[18] and reconﬁrmed recently [19].
Two universally conserved nucleotides, U2585 and A2602,
shown to be essential for chain elongation [20] and E-site
tRNA release [21], respectively, bulges out towards the symme-
try axis and display remarkable ﬂexibility (Figs. 1c and 2c)
[1,2,5–7]. A2602 is a likely candidate for generating PTC con-
formation-alterations as it was shown to posses a diﬀerent con-
formation in each complex studied so far (Fig. 1c) [1,5,15–17].
It is the only ribosomal entity interacting with sparsomycin,
and its binding modes to D50S [1] and H50S [22] provide an
excellent example for antibiotics binding mode that depends
on the ribosomal functional-state. By entering non-occupied
PTC, sparsomycin stacks to A2602 and causes striking confor-
mational alterations in the entire PTC, inﬂuencing, in turn, the
positioning of A-site tRNA [1,5,7]. Conversely, simultaneous
binding of sparsomycin and a P-site analog seems to reduce
the PTC mobility and enhance P-site-tRNA attachment (Fig.
2d).
At the PTC lower end, the ﬂexible U2585 anchors the rotat-
ing-moiety at its aminoacid end. By exploiting its exceptional
ﬂexibility for creating unproductive interactions, A2585 may
be involved in D-isomers exclusion [7,23]. An additional exam-
ple showing U2585 importance is the need to construct the
synergetic antibiotics Synercid with streptograminA/streptogr-
aminB ratio of 70/30. Thus, upon binding to D50S, the strep-
tograminA-compound known to hamper PTC activity,
nucleotide U2585, undergoes a 180 ﬂip PTC [7,23] (Fig.
2e). This striking swing should prohibit U2585 involvement
in the rotatory motion, and consequently trigger ribosomal
counter attempts, rationalizing its poor inhibitory activity.
Only by the addition of the streptograminB component, which
blocks the tunnel and interacts intensively with the streptogr-
aminA component, thus hampering the escape of streptogr-
aminA, this drug acquires its full potent activity. In contrast,
streptograminA causes hardly any U2585 motions in the
PTC of Haloarcula marismortui [24], an archaeon sharing
properties with eukaryotes. Since streptograminB does not
bind to H50S tunnel due to phylogenetic reasons, i.e. the key
nucleotides for binding streptograminB compounds, 2058, is
a guanine instead of the eubacterial adenine, synergisms can-
not be obtained. Diﬀerent streptograminsA binding modes in
ribosomes from H50S and D50S, representing two kingdoms
of life is consistent with the inability of the PTC of H50S to
bind typical eubacterial A- and P-sites antibiotics, such as
chloramphenicol, clindamycin (Fig. 2f) [25] and tiamulin [26].
Thus, reconﬁrming that the PTC possesses considerable con-
formational variability despite its high sequence conservation
[3,27].4. The voyage through the exit tunnel
The entrance to the tunnel providing the path taken by nas-
cent proteins until they emerge out of the ribosome is adjacentto the PTC (Fig. 3a–g). Recent biochemical studies indicate the
tunnel ability to function as a discriminating gate for exporting
proteins, to be involved in co-translational folding events, to
respond to cellular signals and to regulate ribosomal interac-
tions with the ER membrane [28,29], contrary to previous
assumption that the tunnel is a passive path [30].
The spiral nature of the symmetry-related region ensures
nascent proteins entry to the tunnel at a b-strand conforma-
tion, complying with the tunnel narrow entrance. In speciﬁc
cases, likely be connected with nascent-chain–tunnel interac-
tions, motions of rigid residues, such as prolines, may be re-
stricted [31]. Shortly after entering the tunnel, the nascent
peptides pass near a crevice of a size suitable for imitating
nucleation of a few aminoacids at early stages of tunnel pas-
sage (Fig. 3a and b). The boundaries of the crevice are well de-
ﬁned, yet it may be associated with temporary tunnel-diameter
expansion, as observed recently [32].
The tunnel walls are made mostly from rRNA, penetrated
by mobile extended loops of several r-proteins (Fig. 3a, g)
that appear to play key functional roles in the progression
and cotranslational folding of nascent chains. Thus, a swing
of L22 b-hairpin tip across the tunnel around an accurately
placed hinge (Fig. 3c) [7,31] appears to provide the mecha-
nism for elongation arrest, when triggered by speciﬁc cellular
conditions [33]. Protein L22 has a long b-hairpin [34,35],
which extends in the ribosome to the proximity of the tunnel
opening (Fig. 3a) [6,31], hence can provide a communication
route for signaling between the ribosome and the cell. To-
gether with L4, L22 creates a dynamic tunnel-constriction, lo-
cated at the deeper end of the hydrophobic crevice. Neither
L22 nor L4, known to be involved in macrolide-antibiotics
resistance [36,37], interacts directly with typical macrolide-
antibiotics [23]. However, their involvement in resistance to
macrolides, ketolides and azalides [38,39] can be explained
by the interplay between them, since the swung conformation
of L22 b-hairpin tip facilitates its interactions with L4 (Fig.
3d) [40,41]. Moreover, superposition of the structures of the
L22 deletion-mutant acquiring erythromycin resistance on
D50S led to the identiﬁcation of a novel resistance mecha-
nism, based on modiﬁcations of a location that is not adja-
cent to the antibiotics binding site, namely the increase of
the tunnel diameter without corrupting the erythromycin-
binding site, thus providing suﬃcient space for erythromycin
and the growing chain.5. 2058 is not alone
Macrolide-antibiotics, which rank highest in clinical usage,
bind to a pocket located between the hydrophobic crevice
and the tunnel constriction and block nascent proteins pro-
gression in eubacteria (Fig. 3e) [25,31,42,43]. Compared to
the PTC, the tunnel is less conserved. Hence, phylogenetic
diversity plays a considerable role in antibiotics selectivity
and eﬃciency. The identity of nucleotide 2058 (A in all eubac-
teria, G in eukaryotes and archaea, including H. marismortui)
is the key parameter for macrolide selectivity, since no typical
macrolide binds to a tunnel with G2058. Consistently, Aﬁ G
mutation or posttranslational methylation of A2058 acquire
resistance to typical macrolides [44]. Chemically modiﬁed mac-
rolides, such as ketolides and azalides designed to combat mac-
Fig. 3. (a) A section through the large ribosomal subunit (in gray), with docked A- and P-site tRNAs [27] and modeled nascent chain [29]. The
approximate location of the crevice is indicated by a purple circle, and of the macrolide antibiotics binding site by the letter A. (b) The detailed
structure of a section of the tunnel, between the PTC and the tunnel constriction, with the tips of L4 and L22 extended loops, as in (a). C: crevice, ery:
erythromycin. (c) A view into the tunnel (gray), showing the antibiotic troleandomycin (T, yellow) that induces swinging (magenta) of protein L22 b-
hairpin tip (native orientation in cyan). A modeled polypeptide chain (blue) represents a nascent protein with the sequence motif known to cause
SecM (secretion monitor) elongation arrest, located about 150 residues from the N-terminus in XXXXXWXXXXXXXXXXP, where X is any
aminoacid, W is tryptophane and P (proline) is the last aminoacid to be incorporated into the nascent chain. The gray shaded areas show the
approximate locations of the mutations that alleviate the elongation arrest [31]. The arrest essential proline and tryptophane are highlighted in red.
(d) Possible interactions between L22 swung conformation and L4. The ribosomal RNA is shown in gray. (e) The binding modes of several
antibiotics within a cross section of the ribosomal tunnel (doted gray cloud) at the level of the macrolides-binding pocket. The key nucleotides for
macrolide–ketolide binding in domains V (DOM V) and II (DOM II) are marked. For orientation, the approximate PTC location is shown. D and H
designate D50S and H50S, respectively. Ery: erythromycin; Cla: clarithromycin; Rox: roxithromycin; TAO: troleandomycin; Azi: azithromycin (Azi-
1 and Azi-2: the primary and secondary sites of azithromycin in D50S), Azi-H: azithromycin site in H50S; ABT: ABT-773; Tel: telithromycin; Tyl:
tylosin, Spi: spiramycin; Car: carbomycin. (f) Azithromycin main binding pocket in D50S (D(A) = pink on cyan) and H50S (H(A) = red on green),
highlighting the diﬀerences in nucleotide type and orientations. (g) Left: the tunnel opening (light gray cloud) in D50S. The structures of L23 in H50S
and D50S (HL23 and DL23, respectively) are superposed. Two diﬀerent views of proteins H23 and HL39e (that exists only in H50S) are shown on
the right and indicating that although HL39e appears to overlaps the extended loop of DL23, points deeper into the tunnel and occupies only a small
part of the volume taken by L23 loop. The arrows show the direction of the allosteric motion induced by TF binding to L23 globular side, at the
ribosome exterior. (h) The conformations of bridge B2a (H69) in the whole ribosome (yellow) [27] and in D50S (red) [3] together with A- and P-sites
tRNA (as in [27]). The PTC (P) and the decoding site (D), on H44 of the small subunit (30S), are shown in gray.
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of the ribosomal tunnel (Fig. 3e).
The therapeutic eﬀectiveness of macrolide derivatives that
bind to resistant pathogenic strains is explained by diﬀerences
in binding-modes to eubacteria versus eukaryotes or archaea.
Importantly, within the macrolide-pocket of H50S, in addition
to the principal diﬀerence in 2058 identity, the identities of se-ven nucleotides diﬀer from their mates in typical eubacteria.
Among them three are of the opposite type (namely purines in-
stead of pyrimidines and vice versa). Furthermore, most of the
conserved nucleotides have diﬀerent conformations (Fig. 3f).
Consequently, whereas macrolides block most of the D50S
tunnel [23,25,31,40–43], those that bind to H50S occupy a
smaller part of it (Fig. 3f) [40,41] demonstrating the inﬂuence
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2058 identity together with macrolide modiﬁcation determines
whether binding occurs, the conformations of the proximal
nucleotides govern binding-modes and drug eﬀectiveness.6. Nascent-protein emergence and elongation termination
While being elongated, nascent polypeptides portions reach-
ing the tunnel opening interact with ribosome-associated chap-
erones assisting the folding process [45,46]. In eubacteria, the
trigger-factor (TF) is the ﬁrst to fulﬁll this task for cytosolic
proteins. A funnel with dimensions that should allow partial
nascent-protein folding [47] was identiﬁed at the tunnel open-
ing by investigating results of three-dimensional-image-recon-
struction obtained almost two decades ago [48]. Recent
crystallographic studies, performed on complexes of eubacte-
rial TF binding domain with H50S [49] and D50S (D. Baram
and E. Pyetan, to be published), indicate that a sheltered fold-
ing space is formed by TF binding. This space is available for
chaperone-assisted folding at the tunnel opening, and is con-
ﬁned by TF contacts with the ribosome exterior, namely pro-
teins L23 and L29.
L23 is among the few r-proteins displaying dramatic diﬀer-
ences among the three kingdoms of life. Only in eubacteria it
posses a sizable extended loop that penetrates from the subunit
exterior into the tunnel wall (Fig. 3g) [3]. The fully extended
H50S protein, L39e, occupies part of the space consumed by
the bacterial L23 extended loop (Fig. 3g), while running
roughly perpendicular to it. Consistent with biochemical
assignments [50], TF interacts with L23 globular domain of
D50S and H50S in a similar manner, due to the high structural
and sequence conservation of this region. However, although
in H50S this binding induces no conformational changes in
ribosomal components [49], the structure of D50S complexed
with TF suggests signiﬁcant allosteric conformational altera-
tions at L23 extended loop. These alterations vary the tunnel
shape in a fashion that may control the rate and directionality
of nascent proteins entrance into their folding site. They may
also provide a communication path between nascent chains,
the TF, the ribosomal tunnel and additional cellular compo-
nents. The failure of the chimeric complex built of the archaeal
H50S with eubacterial TF to reveal conformational alterations
induced by TF binding, supports its speciﬁcity to eubacteria
kingdom. It also indicates that diﬀerent ribosomal-associated
chaperones may bind in a similar way, but their function in
assisting protein traﬃcking into the folding cradle, is species
or kingdom dependent.
Elongation termination is accompanied by the dissociation
of the assembled ribosome to its two subunits; a process trig-
gered by the attachment of EF-G together the ribosomal-recy-
cling factor (RRF). The structure of D50S complexed with D.
radiodurans RRF shows that RRF binding causes a consider-
able loss of order of the intersubunit bridge connecting the
PTC with the decoding center (R. Zarivach, to be published).
This bridge, called H69 or B2a, is a highly ﬂexible [3,17], thus
readily disordered, as in H50S wild-type [51]. It is likely that
the ribosome beneﬁts from H69 ﬂexibility beyond its participa-
tion in intersubunit bridging. Its proximity to the A- and P-
sites suggests that it acts as a ‘‘crane’’ assisting translocation
[17]. This multi-task feature is also a constituent of the PTCcavity upper rim (Fig. 3h) and as such it is instrumental for
accurate substrate positioning [1,6]. Linking H69 functional
disorder with ribosome dissociation is consistent with our pre-
vious proposal that inducing disorder in pivotal features [17] is
a common ribosomal strategy for avoiding unproductive
events. Hence, we conclude that the creation and the disrup-
tion of bridge B2a are key events in the initiation and termina-
tion of protein biosynthesis.7. Conclusions
Ribosomes are ribozymes that position their substrates at
stereochemistry appropriate for peptide-bond formation, poly-
peptide elongation, and substrate-mediated catalysis. The
identiﬁcation of the internal sizable symmetrical region con-
taining the ribosomal catalytic site, which provides the frame
for substrate placement, suggests that ribosomes evolved from
gene-fusion of two structurally similar catalytic domains. The
PTC architecture implies spiral rotation of the aminoacylated-
tRNA3 0 end within a precisely designed pattern in concert with
the sideways translocation of the mRNA/tRNA complex.
Guided and anchored by ribosomal components, this motion
directs nascent chains entry into the exit tunnel at extended
conformation, complying with the tunnels narrow entry.
This tunnel possesses dynamic properties enabling its partic-
ipation in polypeptide elongation and arrest, sequence discrim-
ination and signaling to various cellular components, including
the ER membrane. At the tunnel opening eubacterial cytosolic
proteins undergo TF aided cotranslational folding, controlled
by protein L23 mobility. Conformational alterations of the
intersubunit bridge connecting the catalytic site with the
decoding center, induced by the RRF, seem to play a key role
in protein biosyntheses termination steps.
Comparative analysis of antibiotics interactions with a
eubacterial pathogen-model and an archaeon sharing proper-
ties with eukaryotes showed that despite the ribosomal conser-
vation, phylogenetic and conformational variations within the
antibiotics binding pockets allow drug selectivity, hence facili-
tating therapeutical usage. Although the identity of nucleotide
2058 is the primary determinant for typical macrolides bind-
ing, subtle conformational diﬀerences in the macrolide pocket
govern the antibiotics clinical eﬀectiveness.
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